FDA's Next-Gen Sequencing Oversight To Rely On 'Well-Curated' Databases
This article was originally published in The Gray Sheet
Executive Summary
The agency will not be requiring separate studies to prove clinical validity for every new next-generation-sequencing product. Instead, established databases with “built-in levels of evidence” will likely serve as the foundation for clearance and approval in many instances, officials say.